BioSpace News Archive

Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger.

22nd Century Group, Inc., a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very-low nicotine content tobacco, and hemp/cannabis research, reports that it is fully prepared to partner with the U.S. Food and Drug Administration to launch its VLN® reduced nicotine content cigarette brand and license its reduced nicotine content tobacco technology to every cigarette manufacturer.

Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline’s Advair Diskus®1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.

- New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia -

Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2021 on Monday, May 10 at 4:30 p.m. ET / 1:30 p.m. PT .

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter after market close on Tuesday, May 4, 2021 .

Invitae Corporation, a leading medical genetics company, announced its plans to open a new laboratory and production facility in North Carolina to further expand its capacity to meet the growing demand for genetic testing services globally.

QIAGEN’s innovative technology integrates sample preparation and detection in a single kit, enabling throughput of more than 670 tests per PCR cycler in an eight-hour shift

Edwards Lifesciences reported financial results for the quarter ended March 31, 2021.